http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106908605-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N21-554 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N15-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N15-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N21-552 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 |
| filingDate | 2017-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106908605-B |
| titleOfInvention | Application of the eLtaS albumen as the drug target for preventing and treating insulin resistance related disease |
| abstract | Application the invention discloses eLtaS albumen as the drug target for preventing and treating insulin resistance related disease.It is demonstrated experimentally that eLtaS albumen can inhibit insulin in conjunction with membrane receptor protein, the receptor phosphorylation that inhibits insulin with target cell ining conjunction with, reduce insulin-mediated, inhibit insulin-mediated cell-signaling pathways key molecule activation, inhibit insulin-mediated sugar transport ability, inhibit insulin-mediated Sugar intake ability, the blood sugar reducing function for inhibiting insulin, the concentration, the raising postprandial blood sugar concentration, reduction sugar tolerance etc. that improve Triglycerides in Serum.Therefore, eLtaS albumen can be used as the drug target for preventing and treating insulin resistance related disease, have important application value. |
| priorityDate | 2017-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 395.